iScience (Nov 2024)

Inhibition of cathepsin L ameliorates inflammation through the A20/NF-κB pathway in endotoxin-induced acute lung injury

  • Shiyi Yang,
  • Kaijun Chen,
  • Jinkang Yu,
  • Zhangchu Jin,
  • Min Zhang,
  • Zhouyang Li,
  • Yang Yu,
  • Nanxia Xuan,
  • Baoping Tian,
  • Na Li,
  • Zhengtong Mao,
  • Wenbing Wang,
  • Tianpeng Chen,
  • Yinfang Wu,
  • Yun Zhao,
  • Min Zhang,
  • Xia Fei,
  • Songmin Ying,
  • Wen Li,
  • Fugui Yan,
  • Xingxian Zhang,
  • Gensheng Zhang,
  • Huahao Shen,
  • Zhihua Chen

Journal volume & issue
Vol. 27, no. 11
p. 111024

Abstract

Read online

Summary: Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a severe inflammatory condition that remains refractory; however, its molecular mechanisms are largely unknown. Previous studies have shown numerous compounds containing 4-indolyl-2-aminopyrimidine that display strong anti-inflammatory properties. In our research, we identified that a 4-Indole-2-Arylaminopyrimidine derivative named “IAAP” suppressed lipopolysaccharide (LPS)-induced inflammation. Immunoprecipitation and liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified that IAAP interacts with a lysosomal cysteine protease, cathepsin L (CTSL), and restrains its activity. The nuclear factor kappa B (NF-κB) family plays a central role in controlling innate immunity. Canonical NF-κB activation, such as stimulation with lipopolysaccharide (LPS), typically involves the degradation of A20. We observed that IAAP suppression of CTSL prevented the LPS-induced degradation of A20, thereby ameliorating NF-κB activation. This study identifies CTSL as a crucial regulator of A20/NF-κB signaling and suggests IAAP as a potential lead compound for developing drugs to treat ALI/ARDS.

Keywords